Table 2.

Clinical characteristics, effectiveness and safety of the two groups

Characteristics	Standard-dose group (n = 146)	Pre-over-dose group (n = 24)	Over-dose group (n = 24)
Accumulative Doxorubicin dose (mg/m2)	364.04 ± 63.81	421.15 ± 47.39	714.38 ± 210.09
ORR (%)	15.07%	100%	16.67%
DCR (%)	58.9%	100%	66.67%
Median-PFS (months)	6 (95%CI: 5.8–6.5)	8.15 (95%CI: 5.8–9.5)	4 (95%CI: 2.0–5.8)
Incidence of cardiotoxicity (%)	3.42%	0%	4.17%

Notes: Data are presented as numbers (percentages) or means ± standard deviations

Abbreviations: ORR objective response rate, DCR disease control rate, Median-PFS median progression-free survival